Erratum to: Increased serum potassium affects renal outcomes: A post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial (Diabetologia DOI: 10.1007/s00125-010-1922-6);Increased serum potassium affects renal outcomes: A post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial

Diabetologia

Volumn 54, Issue 1, 2011, Pages 44-50

  Miao, Y ^a   Dobre, D ^a   Lambers Heerspink, H J ^a   Brenner, B M ^b   Cooper, M E ^c   Parving, H H ^d,e   Shahinfar, S ^f   Grobbee, D ^g   De Zeeuw, D ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^d Mental Health Services CPH   (Denmark)

^e AARHUS UNIVERSITY   (Denmark)

^f CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^g UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Angiotensin receptor blocker; Losartan; Nephropathy; Potassium; Type 2 diabetes

Indexed keywords

CREATININE; LOSARTAN; PLACEBO; POTASSIUM;

ADULT; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; FEMALE; HUMAN; HYPERKALEMIA; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; POST HOC ANALYSIS; POTASSIUM BLOOD LEVEL; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENAL PROTECTION; RISK FACTOR; TREATMENT OUTCOME;

EID: 79953787215     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-011-2215-4     Document Type: Erratum

References (25)

1. Keane WF, Brenner BM, de Zeeuw D et al (2003) The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int 63:1499-1507 (Pubitemid 36350016)
2. Raine AE (1993) Epidemiology, development and treatment of end-stage renal failure in type 2 (non-insulin dependent) diabetic patients in Europe. Diabetologia 36:1099-1104
3. Brenner BM, Cooper ME, de Zeeuw D et al (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869
4. Lewis EJ, Hunsicker LG, Clarke WR et al (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851-860
5. Desai A (2008) Hyperkalemia associated with inhibitors of the renin-angiotensin-aldosterone system: balancing risk and benefit. Circulation 118:1609-1611
6. van Nieuwkoop C, Ijpelaar DH, Bolk JH (2007) Treating proteinuria in a diabetic patient despite hyperkaliemia due to hyporeninaemic hypoaldosteronism. Neth J Med 65:75-77 (Pubitemid 46332375)
7. Palmer BF (2004) Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med 351: 585-592
8. Takaichi K, Takemoto F, Ubara Y, Mori Y (2007) Analysis of factors causing hyperkalemia. Intern Med 46:823-829 (Pubitemid 47261663)
9. Desai AS, Swedberg K, McMurray JJ et al (2007) Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program. J Am Coll Cardiol 50:1959-1966 (Pubitemid 350046342)
10. Brenner BM, Cooper ME, de Zeeuw D et al (2000) The losartan renal protection study - rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan). J Renin Angiotensin Aldosterone Syst 1:328-335
11. Kratz A, Ferraro M, Sluss PM, Lewandrowski KB (2004) Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Laboratory reference values. N Engl J Med 351:1548-1563
12. Pitt B, Bakris G, Ruilope LM, DiCarlo L, Mukherjee R (2008) Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circulation 118:1643-1650
13. Weinberg JM, Appel LJ, Bakris G et al (2009) Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapy. Arch Intern Med 169:1587-1594
14. Mitterbauer C, Heinze G, Kainz A, Kramar R, Horl WH, Oberbauer R (2008) ACE-inhibitor or AT2-antagonist therapy of renal transplant recipients is associated with an increase in serum potassium concentrations. Nephrol Dial Transplant 23:1742-1746 (Pubitemid 351767758)
15. Maddirala S, Khan A, Vincent A, Lau K (2008) Effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on serum potassium levels and renal function in ambulatory outpatients: risk factors analysis. Am J Med Sci 336: 330-335
16. Han SW, Won YW, Yi JH, Kim HJ (2007) No impact of hyperkaliemia with renin-angiotensin system blockades in maintenance haemodialysis patients. Nephrol Dial Transplant 22:1150-1155
17. Einhorn LM, Zhan M, Hsu VD et al (2009) The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med 169:1156-1162
18. Lush DJ, King JA, Fray JC (1993) Pathophysiology of low renin syndromes: sites of renal renin secretory impairment and prorenin overexpression. Kidney Int 43:983-999 (Pubitemid 23137082)
19. Clark BA, Brown RS, Epstein FH (1992) Effect of atrial natriuretic peptide on potassium-stimulated aldosterone secretion: potential relevance to hypoaldosteronism in man. J Clin Endocrinol Metab 75:399-403
20. Mayan H, Kantor R, Farfel Z (2001) Trans-tubular potassium gradient in patients with drug-induced hyperkalemia. Nephron 89:56-61 (Pubitemid 32799834)
21. Bailey IR, Thurlow VR (2008) Is suboptimal phlebotomy technique impacting on potassium results for primary care? Ann Clin Biochem 45:266-269
22. Cornes MP, Ford C, Gama R (2008) Spurious hyperkaliemia due to EDTA contamination: common and not always easy to identify. Ann Clin Biochem 45:601-603
23. Weir MR, Rolfe M (2010) Potassium homeostasis and renin - angiotensin-aldosterone system inhibitors. Clin J Am Soc Nephrol 5:531-548
24. Vogt L, Navis G, de Zeeuw D (2005) Individual titration for maximal blockade of the renin-angiotensin system in proteinuric patients: a feasible strategy? J Am Soc Nephrol 16(Suppl 1):S53-S57 (Pubitemid 41725084)
25. Frimodt-Moller M HNA, Strandgaard S, Kamper AL (2009) Feasibility of combined treatment with enalapril and candesartan in advanced chronic kidney disease. Nephrol Dial Transplant